Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma
The UR models show promise in predicting the efficacy and prognosis of combined targeted therapy and immunotherapy in unresectable hepatocellular carcinoma, particularly highlighting the importance of ultrasound assessments three months post-treatment.
Authors
- Shuqun Cheng (ORCID: https://orcid.org/0000-0001-6760-7470)
- Yiran Li (ORCID: https://orcid.org/0000-0002-0768-3495)
- Zonghan Liu (ORCID: https://orcid.org/0000-0003-2553-8993)
- Kang Wang (ORCID: https://orcid.org/0000-0001-7415-5134)
- Yi Qian (ORCID: https://orcid.org/0000-0001-5671-916X)
- Yan Chen (ORCID: https://orcid.org/0000-0002-2793-612X)
- Yijun Gu
- Dong Jiang
- Haozheng Jiang
Institutions
- Second Military Medical University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- Case Western Reserve University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1371/journal.pone.0334099
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00